The things I'm worried about is their constant focus on EBITDA which doesn't take into account 132% increase in share-based compensation and increase in acquisition costs.
Firstly, share-based compensation is just another form of employee expenses/labour costs.
Secondly, as a company that enjoys an acquisition or two would you not say that acquisition costs related to legal, due diligence, valuation and other business combination costs is taken into account as a part of the acquisition? The big jump from sub-500k to $3.4m relates to PFS and they're indicating further acquisition related costs to complete the acquisition.
I haven't reduced my position, but being a shareholder, the PFS acquisition can't come soon enough because the core business of G&I is not going as well as the current valuation.
Will only top up below $3 until the PFS acquisition gets done and then reassess.
- Forums
- ASX - By Stock
- 1H 2020 Results - The good & The Bad & The confusion
The things I'm worried about is their constant focus on EBITDA...
Featured News
Add EML (ASX) to my watchlist
(20min delay)
|
|||||
Last
65.5¢ |
Change
-0.005(0.76%) |
Mkt cap ! $247.7M |
Open | High | Low | Value | Volume |
66.0¢ | 66.5¢ | 64.5¢ | $403.3K | 613.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 28081 | 65.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
66.5¢ | 151017 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 28081 | 0.655 |
4 | 91943 | 0.650 |
3 | 27521 | 0.645 |
6 | 41745 | 0.640 |
1 | 1576 | 0.635 |
Price($) | Vol. | No. |
---|---|---|
0.665 | 141017 | 4 |
0.670 | 31591 | 3 |
0.675 | 28841 | 4 |
0.680 | 19493 | 4 |
0.685 | 20000 | 1 |
Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
Featured News
EML (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
SPONSORED BY The Market Online